Is BLRX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

495 people get BLRX articles and Market Currents by email alert.

Get email alerts on BLRX »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

BioLineRx Pipeline Returns To The Winner's Circle
Len Zehr • Wed, May 1
Upcoming Trial Data May Help Salvage Bioline Rx
Brian L. Wilson • Wed, Apr 3 • 1 Comment
BioLineRx: Upcoming Catalyst With Potential Multi Billion-Dollar Schizophrenia Drug
Scott Matusow • Tue, Jan 15 • 23 Comments
BioLineRx: Israeli Biotech Incubator With Multiple Near-Term Clinical Catalysts
Mike Havrilla • Thu, Dec 6, 2012
BioLine Is Approaching Its Moment Of Truth
Bioassociate Consulting • Mon, Dec 3, 2012
A New And Interesting Addition To The Hep C Clinical Pipeline
Leonard O'Brien • Wed, Oct 17, 2012 • 3 Comments
BiolineRx Enters The Oncology Field With In-Licensing Deal
Leonard O'Brien • Wed, Sep 5, 2012 • 1 Comment
BioLineRx: Upside Greater Than Stated By Analyst
Bioassociate Consulting • Thu, Jul 5, 2012 • 1 Comment
BioLineRx: An Israeli Biotech Incubator
Mike Havrilla • Thu, Jun 21, 2012 • 2 Comments
Closer Look: BioLineRx Snags Another Hep-C License Agreement
M. E. Garza • Tue, Feb 7, 2012 • 2 Comments
BioLineRx: Strong Speculation Bio-Pharma, Strong Acquisition Target
Scott Matusow • Fri, Feb 3, 2012 • 6 Comments

BioLine Is Approaching Its Moment Of Truth
Bioassociate Consulting • Mon, Dec 3, 2012

China Biotech In Review: Mindray Medical Buys U.S. Ultrasound Company
ChinaBio Today • Sun, Jun 16
AbbVie's Latest Drug Deal Marks A Shift In The Celiac Disease Therapeutics Field
Bioassociate Consulting • Mon, May 20 • 1 Comment
A Capital-Efficient Prescription For New Drugs: Raghuram 'Ram' Selvaraju
Life Sciences Report • Thu, Nov 1, 2012 • 3 Comments
Is The Hep C Drug Pipeline Beginning To Crack?
Bioassociate Consulting • Thu, Aug 16, 2012 • 2 Comments
Undervalued Biotech Stocks In Non-U.S. Markets: Part 1
Bioassociate Consulting • Wed, Jul 25, 2012 • 4 Comments
The Race For The Next Blockbuster Schizophrenia Drug
Bioassociate Consulting • Thu, Jul 19, 2012 • 2 Comments
5 High-Risk, High-Reward Biopharma Stocks
Scott Matusow • Tue, Feb 14, 2012 • 19 Comments

Bioline RX's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Mar 12

BioLineRx Enters into Collaboration to Develop and Commercialize Hepatitis C Drug with CTTQ, Leading Chinese Pharma Company for Liver Disease Therapeutics

Business Wire (Jun 10, 2013)
BioLineRx Enrolls First Patient in Phase 2 Clinical Trial for BL-8040, for Treatment of Leukemia

Business Wire (Jun 6, 2013)
BioLineRx Enters into “At-The-Market” Offering Agreement with Stifel, Nicolaus & Company

Business Wire (May 17, 2013)
BioLineRx to Present at the Oppenheimer 14th Annual Israeli Conference on May 12th

Business Wire (May 9, 2013)
BioLineRx Reports First Quarter 2013 Results

Business Wire (May 7, 2013)
BioLineRx's BL-7010, for the Treatment of Celiac, to be Presented at Two Leading Conferences

Business Wire (May 2, 2013)
BioLineRx to Report First Quarter 2013 Results on May 7, 2013

Business Wire (Apr 30, 2013)
BioLineRx Enrolls First Patient in Phase I/II Clinical Trial for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C

Business Wire (Apr 29, 2013)
BioLineRx to Present at the 12th Annual Needham Healthcare Conference in New York on April 30, 2013

Business Wire (Apr 18, 2013)
BioLineRx Announces Positive Phase II Results for BL-7040, an Orally Available Treatment for Inflammatory Bowel Disease

Business Wire (Apr 17, 2013)
BioLineRx Receives Regulatory Approval to Commence Phase II Clinical Trial for BL-8040, for Treatment of Leukemia

Business Wire (Apr 10, 2013)
Movers & Shakers: Monday’s biggest gaining and declining stocks

at MarketWatch.com (Sep 25, 2012)
Movers & Shakers: Tuesday’s biggest gaining and declining stocks

at MarketWatch.com (Sep 25, 2012)
Stocks to Watch: Stocks to Watch Wednesday: Jabil Circuit

at MarketWatch.com (Sep 25, 2012)
Movers & Shakers: Tuesday’s biggest gaining and declining stocks

at MarketWatch.com (Jun 5, 2012)

BLRX vs. ETF Alternatives

Company Description

BioLineRx, Ltd. operates as a clinical-stage biopharmaceutical development company worldwide. Its clinical therapeutic candidates under development include BL-1020, a Phase IIb completed product for the treatment of schizophrenia; BL-1040, a Phase I/II clinical trial completed medical device... More

Sector: Healthcare

Industry: Biotechnology

Country: Israel

All
| Earnings
| Dividends
| M&A
| On the move

Monday, June 10, 11:51 AM BioLineRx (BLRX +4.2%) says it's signed an out-licensing agreement with Jiangsu Chia-tai Tianqing Pharmaceutical for the development and commercialization of BL-8030, an oral treatment for Hepatitis C. The agreement gives the Chinese biotech exclusive rights to develop, manufacture and commercialize BL-8030 in China and Hong Kong. Jiangsu will pay an upfront license fee plus future milestone payments, giving the deal a potential value of around $30M. Comment! [Healthcare, Global & FX, On the Move]
Thursday, June 6, 11:15 AM BioLineRx (BLRX +1.3%) says it's enrolled the first patient in a Phase 2 trial for BL-8040, for the treatment of acute myeloid leukemia. In addition to receiving regulatory approval for commencing the trial in the U.S.this past April, it recently received regulatory approval from the Israeli Ministry of Health to conduct the trial in Israel as well. The activation of Israeli sites is anticipated during the next few weeks. Comment! [Healthcare, On the Move]
Friday, May 17, 12:36 PM BioLineRx (BLRX -0.6%) enters into an at-the-market sales agency agreement with Stifel Nicolaus. Under the terms of the agreement, BLRX may from time to time, in its discretion, sell up to a maximum of $20M ADSs. Each ADS represents ten ordinary shares. Comment! [Healthcare]
Wednesday, April 17, 7:33 AM BioLineRx (BLRX) says Phase IIa results for its IBD treatment Bl-7040 are positive as the drug is safe and effective. 50% of those enrolled in the proof-of-concept study met the primary endpoint while the remainder of patients were stable or exhibited marginal improvement. Still reeling from the March discontinuation of clinicals for an antipsychotic drug, today's announcement was the second bit of good news for BLRX this month: last week, the company got clearance to begin Phase IIa trials for its Leukemia drug. Comment! [Healthcare]
Wednesday, April 10, 7:57 AM BioLineRx (BLRX) trades higher before the bell after saying it received regulatory approval to commence a Phase IIa trial for its BL-8040 Leukemia drug. The primary endpoints are safety and tolerability. BLRX lost over half its market cap in March after discontinuing a clinical trial for an antipsychotic. Shares +7% premarket. Comment! [Healthcare, On the Move]
Wednesday, March 20, 12:10 PM BioLine (BLRX -51%) craters after discontinuing Phase II/III Clarity trials for its antipsychotic-drug BL-1020, saying it wasn't effective when compared with the antipsychotic Risperidone, its primary efficacy endpoint. The company plans to complete its analysis of the data to determine if there may be future potential for the product. As a result of the discontinuation, the company expects to incur a $6M to $7M reduction in planned R&D expenses for the rest of 2013 and part of 2014. Comment! [Healthcare, On the Move]
Wednesday, March 13, 3:09 PM Bioline RX (BLRX -1.8%) gives back the days gains and more, despite receiving approval from French regulatory authorities to start Phase I/II trials for BL-8020, an oral, interferon-free treatment for the Hepatitis C virus. The study, to be conducted at two clinical sites in France, will evaluate the efficacy, safety and tolerability of BL-8020 in patients infected with HCV, and includes HCV-infected patients of any genotype who have previously failed or relapsed following treatment with the standard-of-care. Comment! [Healthcare, On the Move]
Thursday, February 28, 8:38 AM BioLineRx (BLRX) adds its BL-9010 compound (previously called EDP-14) for treating severe and persistent asthma to its main therapeutic pipeline after "extremely impressive and convincing" pre-clinical data. Shares +3.8% but have been a bit volatile premarket. (PR) 1 Comment [Healthcare, On the Move]
Monday, February 4, 1:23 PM Shares of BioLineRX (BLRX -15%) tank after the drug developer repeats its plan to report interim results from Phase II/III testing of its acute schizophrenia treatment BL-1020 during the week of March 18, amid speculation of less-than-stellar results. The interim analysis will be performed by a fully independent, external Data Monitoring Committee. 1 Comment [Healthcare, On the Move, Global & FX]
Monday, January 7, 3:36 PM BioLineRx (BLRX +2.3%) says Phase II/III results on BL-1020, an antipsychotic for the treatment of schizophrenia, are expected during the week of March 18. The interim analysis, which measures the effect of the drug on cognitive function, will be performed on data of approximately 235 randomized patients from 27 sites in Romania and India. Comment! [Healthcare, On the Move]
Tuesday, October 16, 2012, 1:31 PM BioLineRx (BLRX +5.9%) trades higher after saying it's completed pre-clinical development of its BL-8020 drug candidate, an oral treatment for Hepatitis C. The company plans to initiate a Phase I/II safety and efficacy study in Europe starting early next year and is expecting to receive regulatory approvals from the appropriate authorities by year's end. Comment! [Healthcare, On the Move]
Monday, September 24, 2012, 9:29 AM BioLineRx (BLRX) surges 18.5% after receiving a U.S. patent for its BL-1020 treatment for schizophrenia, which is in Phase II/III trials. The new patent will be valid until 2031, adding nine years to the drug's protection. BioLineRx says BL-1020's market potential has strengthened over the past several months following the failure of rival drugs in late-stage trials. (PR) Comment! [Healthcare, On the Move]
Monday, August 13, 2012, 10:03 AM BioLine RX (BLRX) -7.8% after the biopharmaceutical development company said on Friday that it is offering to sell up to $75M of mixed securities. (filing) Comment! [Healthcare, On the Move]
Thursday, July 19, 2012, 1:45 PM The schizophrenia drug field has its problems, says SA author Tiran Rothman. The treatments are inadequate, with under 50% of patients responding well to them and 20% not responding at all. That, plus a patent cliff presents an opportunity for firms developing the next generation of medicines. These include Lundbeck (HLUKF.PK), Targacept (TRGT), Bioline Rx (BLRX) and Addex Therapeutics (ADDXF.PK). Comment! [Healthcare, Quick Ideas]
Tuesday, June 5, 2012, 9:29 AM Israel-based biopharma drug developer BioLineRx (BLRX) +6% premarket after saying it received two notices of allowance from the U.S. Patent Office related to treatments for neuropathic pain. Comment! [Healthcare, On the Move]
Monday, March 5, 2012, 9:19 AM BioLineRx (BLRX) +7.2% premarket after saying it received approval to start a Phase II trial of its BL-7040 oral treatment for inflammatory bowel disease. A successful clinical trial could herald a breakthrough in the treatment of IBD, as many current treatments cause severe side effects and are ineffective in up to 40% of patients. Comment! [Healthcare, On the Move]

nsahbti
$BLRX target lowered to $7 http://bit.ly/Zw74Uh
Mar 20, 11:10 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

nsahbti
$BLRX falls on Schizo but still has good pipeline
Mar 20, 11:07 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Derrik Lattig
$BLRX fall nearly 50% after announced drug failure
Mar 20, 10:58 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
Alerted via article $BLRX @ $2.85 @ http://seekingalpha.com/a/ntld hit $4.80 last week, sold off on needless company PR to $3.80
Feb 5, 9:56 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

BLRX BioLineRX Ltd.

BLRX

BioLineRX Ltd.